Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
Phase 2 results have been published in obesity (Jastreboff and colleagues, N Engl J Med, 2023) and in type 2 diabetes (Rosenstock and colleagues, Lancet, 2023), and the compound has since progressed into the phase 3 TRIUMPH programme
The confirmatory secondary endpoints included the change in the 6-min walking distance, a hierarchical composite of death and heart failure events
As exciting as the effects of GLP-1 drugs are on cancer and heart health, dont sleep on the possibility that pharma companies will eventually test versions of these drugs that are explicitly focused on improving cognitive function
Insulin and leptin in the blood stream may be stimulated by novel therapeutics
GLP-1 Weight Loss Drugs: Coverage Under Medicaid and Other Health Plans Last Updated: March 2025 Over the past six months, states have been proactive in their consideration or reconsideration of next steps pertaining to coverage of Glucagon-like Peptide (GLP)-1s
